{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336767","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2026-08-06T11:40:21+00:00","discovered_at":"2026-08-06T11:45:00.323306+00:00","generated_at":"2026-08-06T11:45:14.868948+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PepGen DSMB recommends advancing PGN-EDODM1 to 12.5 mg/kg; Q2 net loss $17.8M","bullets":["DSMB recommends advancing FREEDOM2-DM1 to 12.5 mg/kg highest dose cohort; no protocol changes.","DSMB also approves OLE dose escalation from 5 mg/kg to 10 mg/kg; 6 of 8 from 5 mg/kg cohort enrolled in OLE.","10 mg/kg cohort fully enrolled, 7 of 8 completed dosing; data expected November 2026.","Q2 2026 net loss $17.8M ($0.26 per share) vs $23.1M ($0.70) in Q2 2025; R&D expenses $12.5M.","Cash $117.2M as of June 30, 2026; sufficient into Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336767","json":"https://secwatch.observer/filing/0001193125-26-336767.json","markdown":"https://secwatch.observer/filing/0001193125-26-336767.md","text":"https://secwatch.observer/filing/0001193125-26-336767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/0001193125-26-336767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000119312526336767/pepg-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:45:14.868948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}